Skip to main content

Ptc Therapeutics(PTCT-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low29.00
Day High29.83
Open:29.48
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
PR Newswire
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
PR Newswire
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
PR Newswire
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
PR Newswire
CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
PR Newswire
PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
PR Newswire
PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
PR Newswire
PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
PR Newswire
PTC Therapeutics Announces Strategic Pipeline Prioritization
PR Newswire
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PR Newswire
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Profile

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.